2.1. Synthesis, purification and chemical characterization of
BK-(1-9), BK-(1-5) and B1 receptor antagonist
BK-(1-9) [RPPGFSPFR], BK-(1-5) [RPPGF] and the
B1 receptor selective antagonist
Lys-(des-Arg9-Leu8)-BK-(1-9)
[KRPPGFSPL] were synthesized by solid-phase peptide synthesis
employing the Fmoc strategy (Chan et al. , 2000), using
NovaSyn-TGA resins (Merck, Kenilworth, NJ, USA). The final unprotected
peptides were purified by HPLC using a DiscoveryBIO® Wide Pore C18
semi-preparative column. Purified products were analysed by MALDI
TOF/TOF Autoflex III Smartbeam mass spectrometer (Bruker Daltonics,
Hamburg, Germany) for synthesis quality control.